OverviewSuggest Edit

ZIOPHARM Oncology is a biopharmaceutical company focused on the discovery and development of new cancer therapies. The Company's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System to turn on and off and precisely modulate gene expression at the cancer site in order to improve the therapeutic index. ZIOPHARM is applying the latest technologies in cancer research to develop safer, more precise therapeutics to improve care and quality of life for patients.
TypePublic
Founded2005
HQBoston, US
Websiteziopharm.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Feb 2019)48(+5%)
Revenue (FY, 2016)$6.9 M(+59%)
Share Price (May 2019)$4.2 (-2%)

Key People/Management at ZIOPHARM Oncology

Laurence J.N. Cooper

Laurence J.N. Cooper

CEO
Francois Lebel

Francois Lebel

Executive Vice President, Research and Development, Chief Medical Officer
David Mauney

David Mauney

Executive Vice President, Chief Business Officer and Interim Chief Operating Officer
Lynn M. Ferrucci

Lynn M. Ferrucci

SVP, Human Resources, Facilities, IT and Administration
Kevin G. Lafond

Kevin G. Lafond

Sr. Vice President Finance, Chief Accounting Officer and Treasurer
Show more

ZIOPHARM Oncology Office Locations

ZIOPHARM Oncology has an office in Boston
Boston, US (HQ)
1 1st Ave #34, Charlestown
Show all (1)

ZIOPHARM Oncology Financials and Metrics

ZIOPHARM Oncology Revenue

ZIOPHARM Oncology's revenue was reported to be $6.86 m in FY, 2016 which is a 58.4% increase from the previous period.
USD

Net income (Q1, 2019)

(13.4m)

EBIT (Q1, 2019)

(13.6m)

Market capitalization (22-May-2019)

688.6m

Closing stock price (22-May-2019)

4.2

Cash (31-Mar-2019)

51.5m
ZIOPHARM Oncology's current market capitalization is $688.6 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

800.0k1.4m4.3m6.9m

Revenue growth, %

72%216%58%

General and administrative expense

15.7m17.6m14.4m14.8m19.9m

R&D expense

42.9m106.8m157.8m45.1m34.1m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

General and administrative expense

3.1m3.4m3.0m2.8m4.3m7.1m3.1m3.8m3.7m3.5m3.6m3.8m3.6m6.2m4.9m4.3m4.1m

R&D expense

12.0m10.8m11.1m10.2m7.5m8.3m9.5m

Operating expense total

9.3m10.0m11.4m12.6m78.5m14.5m20.0m14.0m132.9m12.5m15.6m14.6m14.7m16.3m12.4m12.6m13.6m

EBIT

(9.1m)(9.8m)(11.2m)(11.9m)(78.2m)(14.2m)(18.2m)(12.0m)(131.2m)(10.9m)(14.0m)(13.0m)(13.1m)(16.2m)(12.4m)(12.6m)(13.6m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

68.2m42.8m140.7m81.1m70.9m61.7m

Accounts Receivable

145.0k446.0k508.4m19.0k1.9m

Inventories

1.9m1.1m11.4m23.8m

Current Assets

70.3m44.1m152.5m104.9m90.8m84.3m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

23.6m60.4m53.0m46.1m129.7m118.6m163.8m124.8m109.0m94.7m66.4m97.2m84.4m51.1m40.4m31.7m51.5m

Accounts Receivable

27.0k32.0k208.0k89.0k369.0k25.0k67.0k44.0k13.0k18.0k663.0k1.0m854.0k

Inventories

30.5m

Current Assets

27.3m62.0m54.0m47.8m130.6m123.1m172.5m140.4m126.7m115.7m92.8m125.1m114.9m72.1m53.0m47.2m74.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(57.1m)(31.8m)(120.1m)(165.3m)(54.3m)(53.1m)

Depreciation and Amortization

738.0k462.0k357.0k290.0k369.0k575.0k

Inventories

5.0m809.0k(10.0m)(12.0m)

Accounts Payable

(1.1m)1.6m4.0k(1.9m)4.3m(3.7m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(48.2m)(9.7m)(15.3m)(21.4m)(78.2m)(92.4m)(110.6m)(12.0m)(143.2m)(154.1m)(15.5m)(28.3m)(41.0m)(16.0m)(28.1m)(40.6m)(13.4m)

Depreciation and Amortization

582.0k124.0k217.0k339.0k122.0k236.0k295.0k72.0k155.0k227.0k79.0k167.0k259.0k117.0k255.0k412.0k140.0k

Inventories

30.5m

Accounts Payable

(618.0k)156.0k25.0k1.5m(1.2m)1.1m2.2m(100.0k)23.0k(194.0k)70.0k(75.0k)1.4m(3.8m)(3.8m)(3.1m)152.0k
USDY, 2019

Financial Leverage

1.1 x
Show all financial metrics

ZIOPHARM Oncology News and Updates

Ziopharm Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

- Phase 1 Trial of Sleeping Beauty-TCR-T cell therapy for patients with solid tumors to begin at National Cancer Institute in mid-2019 –- Third-generation Sleeping Beauty CD19-specific CAR-T U.S. trial to begin in 2H2019 –  - Eden BioCell to advance third-generation Sleeping Beauty CAR-T for Greater…

Ziopharm Oncology to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on March 5

BOSTON, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast slide presentation on Tuesday, March 5, at 4:30 p.m. ET to provide a corporate update and discuss financial results for the fourth quarter and yea…

Ziopharm Oncology Completes Enrollment of Controlled IL-12 Monotherapy Expansion Substudy in Phase 1 Brain Cancer Trial

-- Substudy promptly accrued 36 patients in less than six months, with majority of newly enrolled patients receiving low-dose steroids -- -- Substudy promptly accrued 36 patients in less than six months, with majority of newly enrolled patients receiving low-dose steroids --

Ziopharm Oncology Responds to Recent Stock Decline and Clarifies Exclusivity Rights for Clinical Assets

BOSTON, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today responded to the recent decline in the Company’s stock price, which accelerated greatly on December 26, 2018, the same day that the broader market and all indexes were up significantly. To the extent this price d…

Ziopharm Oncology Promotes Dr. David Mauney to President

BOSTON, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that David Mauney, M.D., has been promoted to President effective immediately. Dr. Mauney, who joined Ziopharm in 2017 as Executive Vice President and Chief Business Officer, will continue to report to …

ZIOPHARM Oncology Blogs

Ziopharm Oncology Announces FDA Fast Track Designation for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Recurrent Glioblastoma

Ziopharm Oncology Announces FDA Fast Track Designation for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Recurrent Glioblastoma Content Import Mon, 04/01/2019 - 07:08 Ziopharm Oncology Announces FDA Fast Track Designation for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Recurrent …

Ziopharm Oncology CEO to Present at the CAR-TCR Summit Europe

BOSTON , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that Chief Executive Officer Laurence Cooper , M.D., Ph.D, is scheduled to present and participate in a panel discussion on Feb. 26 at the CAR-TCR Summit Europe in London .

Ziopharm Oncology Presenting at the 37th Annual J.P. Morgan Healthcare Conference

BOSTON, MA, January 10, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) Laurence Cooper, M.D., Ph.D., Chief Executive Officer, today is presenting at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco at 9 a.m. PT/12 noon ET.

Ziopharm Oncology Posts Letter to Stockholders

BOSTON , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today posted and released the following letter: Dear Fellow Stockholders, With the 37 th Annual J.P. Morgan Healthcare Conference upon us, we wanted to communicate directly with our shareholders.

Ziopharm Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference

BOSTON , Dec. 21, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer, will present at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2019 , at 9 a.m. PST .

Ziopharm Oncology and TriArm Therapeutics Establish Joint Venture to Develop and Commercialize Sleeping Beauty CAR T in China, Taiwan and Korea

-- Joint venture to operate as Eden BioCell -- -- TriArm Therapeutics, a Panacea Venture Healthcare company, to fund Eden BioCell with up to $35M -- -- Ziopharm to license rights of third-generation Sleeping Beauty CD19-specific CAR-T cell therapies to Eden BioCell -- -- Eden BioCell to be owned
Show more

ZIOPHARM Oncology Frequently Asked Questions

  • When was ZIOPHARM Oncology founded?

    ZIOPHARM Oncology was founded in 2005.

  • Who are ZIOPHARM Oncology key executives?

    ZIOPHARM Oncology's key executives are Laurence J.N. Cooper, Francois Lebel and David Mauney.

  • How many employees does ZIOPHARM Oncology have?

    ZIOPHARM Oncology has 48 employees.

  • Who are ZIOPHARM Oncology competitors?

    Competitors of ZIOPHARM Oncology include Regenxbio, Syros Pharmaceuticals and Oxford Genetics.

  • Where is ZIOPHARM Oncology headquarters?

    ZIOPHARM Oncology headquarters is located at 1 1st Ave #34, Charlestown, Boston.

  • Where are ZIOPHARM Oncology offices?

    ZIOPHARM Oncology has an office in Boston.

  • How many offices does ZIOPHARM Oncology have?

    ZIOPHARM Oncology has 1 office.